Cervical cancer screening before hysterectomy in pelvic organ prolapse patients: Is it essential? A case series
Downloads
HIGHLIGHTS
- More advanced cervical precancerous histopathological findings compared with cervical cytology are observed in POP patients undergoing vaginal hysterectomy.
- Routine use of preoperative biopsy or ultrasound in POP patients undergoing vaginal hysterectomy cannot be recommended.
ABSTRACT
Objective: Pelvic organ prolapse (POP) results from weakening of the pelvic floor musculature. The reported prevalence of unexpected premalignant and malignant pathologies following hysterectomy ranges from 0.2 to 0.8%. This study aims to present a case series of patients with POP who underwent vaginal hysterectomy (VH) after preoperative evaluation for abnormal cervical cytology, which subsequently demonstrated more advanced histopathological findings.
Case Series: Case 1: A 55-year-old woman, P3A0, was diagnosed with third-degree uterine prolapse and cystocele. Pap smear revealed atypical glandular cells of undetermined significance (AGUS). Histopathological examination after VH demonstrated vaginitis and metaplastic chronic cervicitis with atypia progressing to mild dysplasia of endocervical epithelial cells/low-grade squamous intraepithelial lesion (LSIL). Case 2: A 62-year-old woman, P5A0, was diagnosed with third-degree uterine prolapse. Pap smear revealed atypical squamous cells of undetermined significance (ASCH). Histopathological evaluation after VH demonstrated high-grade squamous intraepithelial lesion (HSIL) up to carcinoma in situ with microinvasive glandular involvement and focal extension.
Conclusion: Given that cervical cancer remains the second leading cause of mortality among women in Indonesia, preoperative screening for precancerous gynecological lesions and malignancy is strongly recommended.
Tailor HJ, Bhagat VM, Patel PR, et al. Pap smear findings in uterine prolapse: a coincidence or indicator for impending malignancy. International Journal of Medical Science and Public Health. 2015;5(4):819–22. doi: 10.5455/ijmsph.2016.2002 2015375
Jelovsek JE, Maher C, Barber MD. Pelvic organ prolapse. Lancet. 2007;369(9566):1027-38. doi: 10.1016/S0140-6736(07)60462-0. PMID: 1738 2829.
Merrill RM, Layman AB, Oderda G, et al. Risk estimates of hysterectomy and selected conditions commonly treated with hysterectomy. Ann Epidemiol. 2008;18(3):253-60. doi: 10.1016/j. annepidem.2007.10.011. PMID: 18280923.
World Health Organization. Cervical cancer [Internet]. 2023 [cited 2023 Nov 29]. Available from: https://www.who.int/news-room/fact-sheets/ detail/cervical-cancer
Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am. 2007;34(4):739-60, ix. doi: 10.1016/j.ogc.2007.09. 004. PMID: 18061867; PMCID: PMC2762353.
Guthrie D, Bache W. The infrequency of carcinoma of the cervix with complete procidentia. Ann Surg. 1932;96(4):796-800. doi: 10.1097/00000658-193210000-00027. PMID: 17866871; PMCID: PMC1391809.
Aydin S, Bakar RZ, Mammadzade A, et al. The incidence of concomitant precancerous lesions in cases who underwent hysterectomy for prolapse. Journal of Clinical and Analytical Medicine. 2016;7:676-80. doi: 10.4328/jcam.4385.
Grigoriadis T, Valla A, Zacharakis D, et al. Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy? Int Urogynecol J. 2015;26(3):421-5. doi: 10.1007/ s00192-014-2516-5. Epub 2014 Oct 8. PMID: 25293812.
Barakzai S, Koltun-Baker E, Melville SJF, et al. Rates of unanticipated premalignant and malignant lesions at the time of hysterectomy performed for pelvic organ prolapse in an underscreened popula-tion. AJOG Glob Rep. 2023;3(2):100217. doi: 10.1016/j.xagr.2023.100217. PMID: 37275440; PMCID: PMC10232886.
Aimjirakul K, Ng JJ, Saraluck A, et al. A Retrospective cohort study on the prevalence, risk factors, and improvement of overactive bladder symptoms in women with pelvic organ prolapse. Int J Womens Health. 2023;15:1039-46. doi: 10.2147/ IJWH.S413670. PMID: 37469654; PMCID: PMC10352122.
Ramm O, Gleason JL, Segal S, et al. Utility of preoperative endometrial assessment in asymptomatic women undergoing hysterectomy for pelvic floor dysfunction. Int Urogynecol J. 2012;23(7):913-7. doi: 10.1007/s00192-012-1694-2. Epub 2012 Mar 8. PMID: 22398824.
Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102-31. doi: 10.1097/LGT.0000000000000525. Erratum in: J Low Genit Tract Dis. 2020 Oct;24(4):427. doi: 10.1097/LGT.0000000000000563. PMID: 32243 307; PMCID: PMC7147428.
Elbiaa AA, Abdelazim IA, Farghali MM, et al. Unexpected premalignant gynecological lesions in women undergoing vaginal hysterectomy for utero-vaginal prolapse. Prz Menopauzalny. 2015;14(3): 188-91. doi: 10.5114/pm.2015.54344. Epub 2015 Sep 30. PMID: 26528108; PMCID: PMC4612556.
Suphattanaporn O, Saraluck A, Mononai J, et al. Prevalence of precancerous gynecological lesions and gynecological cancer in patients undergoing vaginal hysterectomy for pelvic organ prolapse. Ann Med. 2023;55(2):2273428. doi: 10.1080/0785 3890.2023.2273428. Epub 2023 Oct 26. PMID: 37883921; PMCID: PMC10836294.
Maraqa B, Lataifeh I, Otay L, et al. Prevalence of Abnormal Pap Smears: A Descriptive Study from a Cancer Center in a Low-Prevalence Community. Asian Pac J Cancer Prev. 2017;18(11):3117-21. doi: 10.22034/APJCP.2017.18.11.3117. PMID: 29172288; PMCID: PMC5773800.
Koonmee S, Bychkov A, Shuangshoti S, et al. False-negative rate of papanicolaou testing: A national survey from the Thai Society of Cytology. Acta Cytol. 2017;61(6):434-40. doi: 10.1159/00047 8770. Epub 2017 Jul 25. PMID: 28738387.
Grimes DR, Corry EMA, Malagón T, et al. Challenges of false positive and negative results in cervical cancer screening [Internet]. medRxiv; 2020 [cited 2023 Dec 10]. p. 2020.03.17.20037440. Available from: https://www.medrxiv.org/content/ 10.1101/2020.03.17.20037440v1
Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(7):687-705. doi: 10.1001/jama.2018.10400. PMID: 30140883.
Fleider LA, de Los Ángeles Tinnirello M, Gómez Cherey F, et al. High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting. PLoS One. 2023;18(2):e0279728. doi: 10.1371/journal.pone.0279728. PMID: 36745 662; PMCID: PMC9901754.
Macios A, Nowakowski A. False negative results in cervical cancer screening-risks, reasons and implications for clinical practice and public health. Diagnostics (Basel). 2022;12(6):1508. doi: 10.3390/diagnostics12061508. PMID: 35741319; PMCID: PMC9222017.
Schiffman M, Kinney WK, Cheung LC, et al. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. J Natl Cancer Inst. 2018;110(5):501-8. doi: 10.1093/ jnci/djx225. PMID: 29145648; PMCID: PMC627 9277.
Nuranna L. See and treat: Cervical cancer preven-tion strategy in Indonesia with VIA-DoVIA screening and prompt treatment. The Indonesian Journal of Cancer Control. 2022;2(1):32–8. doi: 10.52830/inajcc.v2i1.70.
Copyright (c) 2025 Ekarini Aryasatiani, Raymond Surya, Dyonesia Ary Harjanti, Florinda Ilona, Chandra Dewi Kartika, Catalya Christina Cantika, Lisda Tenka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
